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Abstract
Background: When administering vancomycin hydrochloride (VCM), the initial dose
is adjusted to ensure that the steady-state trough value (Css-trough) remains within
the effective concentration range. However, the Css-trough (population mean method
predicted value [PMMPV]) calculated using the population mean method (PMM) often
deviate from the effective concentration range. In this study, we used the generalized
linear mixed model (GLMM) for initial dose planning to create a model that accurately
predicts Css-trough, and subsequently assessed its prediction accuracy.
Methods: The study included 46 subjects whose trough values were measured after
receiving VCM. We calculated the Css-trough (Bayesian estimate predicted value [BEPV])
from the Bayesian estimates of trough values. Using the patients’ medical data, we created
models that predict the BEPV and selected the model with minimum information criterion
(GLMM best model). We then calculated the Css-trough (GLMMPV) from the GLMM best
model and compared the BEPV correlation with GLMMPV and with PMMPV.
Results: The GLMM best model was {[0.977 + (males: 0.029 or females: -0.081)] ×
PMMPV + 0.101 × BUN/adjusted SCr – 12.899 × SCr adjusted amount}. The coefficients of
determination for BEPV/GLMMPV and BEPV/PMMPV were 0.623 and 0.513, respectively.
Conclusion: We demonstrated that the GLMM best model was more accurate in
predicting the Css-trough than the PMM.
Keywords: Vancomycin, Therapeutic drug monitoring, Initial dose planning, Generalized
linear mixed model
Background
Vancomycin hydrochloride (VCM) is commonly used to treat methicillin-resistant
Staphylococcus aureus (MRSA) infections but is known to have a narrow safe blood
concentration range. To ensure safe and effective pharmacotherapy, the steady-state
trough value (Css-trough) must be maintained at the effective blood concentration
range of 10–20 μg/mL [1, 2]. The incidence of renal toxicity is known to increase when
the Css-trough exceed 20 μg/mL [3, 4]. Therefore, the VCM dose must be adjusted
using therapeutic drug monitoring (TDM) to keep the Css-trough within the effective
blood concentration range (Fig. 1). This improves the cure rate of infections and the
incidence of renal toxicity [5]. Because VCM has a high rate of renal excretion, the
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dose setting must be determined by the renal function of the patient. Therefore, the
initial dose plan for VCM is set using the population mean method (PMM), which uses
mean values for population pharmacokinetics parameters, creatinine clearance (CLcr)
and weight to estimate the Css-trough (population mean method predicted value,
PMMPV). Then, the estimated Css-trough is used to determine the VCM dose and
infusion time and interval that would maintain an effective blood concentration range.
VCM administration is commenced based on this initial dose plan and after several
days the trough value is measured. We calculate the Css-trough (Bayesian estimate
predicted value, BEPV) from the Bayesian estimate using the measured value and the
population pharmacokinetics parameters. There is a large discrepancy between the
PMMPV and BEPV in cases where the accuracy of the Css-trough determined from the
initial dose plan as predicted by PMM is low. In that case, BEPV often deviates from
the effective blood concentration range. Because the dose plan has to be changed in
such cases, it requires sufficient time that Css-trough achieves the effective blood
concentration range. As a result, the duration of infection is prolonged, the risk of
adverse effects is higher. Therefore, in initial dose plan, it is necessary to devise to
predict highly accurate Css-trough. However, because the predictive accuracy by the
PMM is insufficient, a large discrepancy often exists between the PMMPV and BEPV [6].
PMM is a method of predicting the unknown Css-trough before commencing drug
administration. Statistical modeling has attracted attention as a method of predicting
unknown results using a formula (model) created by extracting only the necessary
information from enormous amounts of data and is used in a variety of fields [7, 8].
One statistical modeling method is the generalized linear mixed model (GLMM), which
is characterized by its ability to use multiple data (explanatory variables) to predict
unknown outcomes (response variables). Medical facilities accumulate a variety of
medical data, but when PMM is used to determine the initial VCM dose, only medical
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Fig. 1 TDM protocol for VCM
Kourogi et al. Theoretical Biology and Medical Modelling  (2017) 14:8 Page 2 of 16
that had a major impact on changes of Css-trough of VCM from patient’s medical data
and created a model that predicts highly accurate Css-trough by applying that informa-
tion to GLMM explanatory variable (Fig. 2). In this study, we created this model and
assessed whether it could predict VCM Css-trough values that were closer to the BEPV
than PMMPV, calculated using the model.
Methods
Subject extraction
This study included 46 patients whose trough values were measured in 3–5 days from
the start of drug administration and were selected from patients who received VCM
(VANCOMYCIN HYDROCHLORIDE for I.V. Infusion “MEEK”, Meiji Seika Pharma,
Tokyo, Japan) drip infusions between August 2008 and March 2015 at Chiyoda
Hospital (Table 1). Exclusion criteria were receiving hemodialysis, outpatients, and
under the age of 18 years.
Calculation of CLcr
The PMM requires the CLcr for calculating the VCM Css-trough values and, therefore,
we first calculated the CLcr for each patient from their sex, age, weight, and serum
creatinine (SCr) at initial dose planning using the Cockcroft-Gault formula (CG
formula, Eq. 1) [9]. SCr was affected by the patient’s muscle mass. Therefore, because
patients with low muscle mass have low SCr levels, we estimate that the CLcr calcu-
lated using the CG formula would high, which overestimates the renal function. In
Japan, to estimate CLcr calculated using the CG formula accurately, if the patient’s SCr
is < 0.6 mg/dL, it is commonly adjusted to 0.6 mg/dL (adjusted SCr) [10]. Therefore, we
used the same method here.
Women
CLcr mL=minð Þ ¼ 140−Age yearsð Þ½   Weight kgð Þ
72  SCr mg=dLð Þ  0:85 ð1AÞ
Men
A B
Fig. 2 Changes in blood concentration after start of VCM administration. Changes in VCM blood concentration
when initial dose planning is performed using (a) PMM and (b) GLMM. ●, Css-trough. The purpose of this study
was to create the model that accurately predicts Css-trough at the initial VCM dose plan
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CLcr mL=minð Þ ¼ 140−Age yearsð Þ½   Weight kgð Þ
72  SCr mg=dLð Þ ð1BÞ
To calculate BEPV, the CLcr is calculated using Eq. 1 even when trough values
are measured. If the SCr level has not reached 0.6 mg/dL then, it is adjusted
accordingly.
Calculation of PMMPV and BEPV
The PMMPV was calculated using CLcr at initial dose planning, weight, VCM dose
conditions (dose, infusion time, and administration interval), and mean values for
population pharmacokinetic parameters [11]. Furthermore, the calculations were
based on the two-compartment model because the distribution of VCM is divided
into the central compartment (blood and tissues which equilibrate rapidly with
blood) and the peripheral compartment (tissues which equilibrate slowly with
blood) [11].
The BEPV was calculated by CLcr at measuring trough value, weight, VCM adminis-
tration conditions (dose, infusion time, and administration interval), and the estimating
the patients’ pharmacokinetic parameters based on the two-compartment model using
the Bayesian estimate.
The PMMPV and BEPV were calculated using the TDM analytical software,
Vancomycin MEEK Ver. 3.0 (Meiji Seika Pharma).
Definition of difference (PMM prediction deviation quantity, PMMPDQ) between BEPV
and PMMPV
This study aimed to create a model that very accurately predicts the VCM Css-trough
using patient medical data. We focused on the medical data having high correlation
with the difference between BEPV and PMMPV. We could reduce the difference
between BEPV and PMMPV by applying the medical data to the GLMM model as
Table 1 Summary of patient characteristics
Characteristic
No. of patients (female/male) 46 (14/32)
Age (years) 77.37 ± 8.79
Height (cm) 157.66 ± 8.59
Weight (kg) 46.66 ± 9.91
BMI (kg/m2) 18.70 ± 3.34
SCr (mg/dL) 0.82 ± 0.35
CLcr (mL/min) 45.37 ± 18.31
BUN (mg/dL) 19.15 ± 11.76
AST (IU/L) 34.70 ± 24.64
ALT (IU/L) 30.46 ± 36.94
CRP (mg/dL) 8.98 ± 7.32
The values are shown as the mean ± standard deviation
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explanation variables. Thus, the difference between BEPV and PMMPV is defined as
the PMM prediction deviation quantity (PMMPDQ, Eq. 2).
PMMPDQ ¼ BEPV − PMMPV ð2Þ
Establishing the basic model that the aimed model is based on
Before creating the model, we first established the minimum configuration model (basic
model) that formed its basis. Here, we attempted to use a model to very accurately
predict the BEPV. Therefore, the response variable used in the model was the BEPV.
Our investigation of the correlation between PMMPV and BEPV indicated that it was
0.702 (Spearman’s rank correlation coefficient). Guilford’s rule of thumb, which is
commonly used as a standard for correlation coefficients, stipulates that correlation
coefficients of 0–0.2, 0.2–0.4, 0.4–0.7, 0.7–0.9, and 0.9–1.0 are “almost none,” “weak,”
“moderate,” “high,” and “extremely high” correlations, respectively [12]. Therefore,
since PMMPV and BEPV are highly correlated, we believe that PMMPV is an appropri-
ate explanatory variable for the model. Based on this, the basic model is expressed as
Eq. 3 and is equivalent to the formula that predicts the Css-trough based on PMM.
BEPV ¼ β1  PMMPV ð3Þ
β1: PMMPV coefficient
Creating the predictor model (GLMM best model) for VCM Css-trough based on GLMM
Figure 3 shows the procedure we used to create the model (GLMM best model). To
create a model with a high predictive accuracy, it is necessary to add effective explana-
tory variables to the basic model. The use of medical data that is highly correlated to
PMMPDQ in the model improves the predictive accuracy. Therefore, the explanatory
Fig. 3 Procedure for creating GLMM best model for estimating Css-trough of VCM based on WAIC. Models
with small WAIC have small predictive errors. We used WAIC to extract effective medical data (fixed and random
effects) and determined the model that accurately predicts BEPV (GLMM best model)
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variables added to the basic model must be medical data that is highly correlated to
PMMPDQ. Thus, to identify medical data as potential explanatory variables that can be
added to the basic model, we first obtained the subjects’ medical data.
Collection of subject medical data (Fig. 3, procedure 1)
To obtain medical data that can potentially be added to the basic model as explanatory
variables, we collected the following subject data: Clinical findings (age, age range
[10-year intervals], aged ≥ 75 or not, sex, height, weight, hospital days since drug
administration commenced), blood test findings (total protein, serum albumin [Alb],
aspartate transaminase [AST], alanine transaminase [ALT], lactate dehydrogenase
[LDH], total bilirubin, blood urea nitrogen [BUN], SCr, adjusted SCr, BUN/SCr, BUN/
adjusted SCr, SCr adjustment amount, SCr adjusted or not, serum Na, serum K, serum
Cl, blood glucose level, c-reactive protein [CRP], white blood cell [WBC], red blood cell
[RBC], hemoglobin [Hb], hematocrit [Ht], platelet [PLT], mean corpuscular volume
[MCV], mean corpuscular hemoglobin [MCH], mean corpuscular hemoglobin concen-
tration [MCHC]), and VCM administration schedule (initial dose, initial daily dose,
single dose, daily dose, infusion time, and number of doses; whether doses were irregu-
larly spaced; and number of days until blood concentration trough values were
measured since drug administration commenced). Then, to extract effective explanatory
variables from the medical data, we conducted the following investigation.
Extraction of medical data (fixed effect candidate 1) correlated to the difference between
BEPV and PMMPV (PMMPDQ, Fig. 3, procedure 2)
When using GLMM, multiple explanatory variables can be included in the model.
However, the creation of a model including all the medical data we obtained would have
produced an inordinate number of model types. Therefore, we first extracted the patient
medical data (explanatory variables) that would be effective when added to the basic
model. Thus, the two GLMM explanatory variables types were the fixed effect (equivalent
to single and multiple regression analyses explanatory variables), which were elements
that predict BEPV (response variable), and random effect, which were elements that chan-
ged the fixed effect coefficient and the intercept values of the model. In accordance with
the software specifications (Stan) used for the GLMM analysis, we used continuous
variables (continuous, such as height and weight) for the fixed effect and discrete variables
(qualitatively non-continuous, such as sex and all conditions) for random variables.
Since the medical data that correlated highly with the PMMPDQ had an appropriate
fixed effect for use in the model, we calculated the Spearman’s rank correlation coeffi-
cient for all medical data and the PMMPDQ.
Medical data (continuous variable) that correlated highly to the PMMPDQ (absolute
value of the correlation coefficient of ≥ 0.2) were identified as fixed effect candidate 1.
Extraction of appropriate medical data (fixed effect candidate 2) for use as fixed effect in
model (Fig. 3, procedure 3)
We wanted to extract medical data from items identified as fixed effect candidate 1 that
would be effective when added to the basic model (Eq. 3). Therefore, we created a
model (Eq. 4) that included each fixed effect candidate 1 item as a fixed effect in the
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basic model and calculated the information criterion (Widely Applicable Information
Criterion, WAIC) for each model.
BEPV ¼ β1  PMMPV þ βFE1  FE1 ð4Þ
β1: PMMPV (fixed effect) coefficient, βFE1: each fixed effect candidate 1 (fixed effect)
coefficients, and FE1: each fixed effect candidate 1 (fixed effect).
WAIC is used to select the model with a high degree of predictive accuracy from
multiple models and is an index for generalization errors (predictive error when
making predictions using the model on unknown patients other than the subjects of
this study). The smaller WAIC is, the higher predictive accuracy of a model is and it is
determined to apply to unknown patients [13]. Therefore, fixed candidate 1 items used
in a model made smaller WAIC than the basic model were considered an appropriate
fixed effect in the GLMM best model and were designated as fixed effect candidate 2.
Determination of fixed effect model (Fig. 3, procedure 4)
To determine the model (fixed effect model) composed of multiple fixed effects
with the smallest predictive error, we created a model (Eq. 5) that included
multiple fixed effect candidate 2 items in the basic model. Additionally, we calcu-
lated the WAIC for all models.
BEPV ¼ β1  PMMPV þ
Xn
i¼1
βFE2i  FE2i ð5Þ
β1: PMMPV (fixed effect) coefficient, βFE2i: ith fixed effect candidate 2 coefficient,
and FE2i: ith fixed effect candidate 2 (fixed effect).
However, n is the upper limit of the number of medical data items corresponding to
fixed effect candidate 2.
Of all the models created, that with the smallest WAIC was selected as the fixed
effect model.
Extracting applicable medical data (random effect candidate) as random effect in the
model (Fig. 3, procedure 5)
Since medical data that is highly correlated to the PMMPDQ has a major effect on
predictive accuracy, we calculated the intra-class correlation coefficient (ICC). Since
medical data with a large ICC related to the PMMPDQ is a likely discrete variable that
can be applied to the model [14], we identified the medical data (discrete variables)
with the largest ICC as random effect candidates.
Determination of GLMM best model (Fig. 3, procedure 6)
To determine the most appropriate predictive model (GLMM best model) with the
smallest predictive error, we created multiple models including random effect candidate
items in the fixed effect model (the model created using Procedure 4 in Fig. 3) and cal-
culated WAIC for each model. Of the created models, that with the smallest WAIC
was selected as the GLMM best model.
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Assessing predictive accuracy of GLMM best model
First, we substituted the subjects’ medical data for all the explanatory variables
(fixed and random effects) in the GLMM best model, which we used to calculate
the Css-trough (GLMMPV). Next, to assess the predictive accuracy of the PMMPV
and GLMMPV for BEPV, we set BEPV as the response variable and investigated
the regression equation and coefficient of determination (R2) when the explanatory
variable was either PMMPV or GLMMPV. The GLMM prediction deviation
quantity (GLMMPDQ) was defined as the difference between BEPV and
GLMMPV (Eq. 6).
GLMMPDQ ¼ BEPV − GLMMPV ð6Þ
Data processing method
We used the statistical analysis software R (ver. 3.2.3) and Microsoft Excel for Mac
(ver. 15.22) to statistically analyze the data. We used functions included in R for our
Spearman’s rank correlation coefficient calculations and Shapiro-Wilk test and the R
package ICC (ver. 2.3.0) for ICC calculations. We used Excel for Mac for simple linear
regression and R2 calculations. A P <0.05 was considered significant for all tests.
We used R, Stan, the R packages rstan, and brms (ver. 2.9, 2.9.0-3, and 0.8.0, respect-
ively) for GLMM analysis and WAIC calculations. We used the Bayesian estimation
with Hamilton Monte Carlo to estimate the model coefficient. We used Rhat for the
convergence test of the Bayesian estimation and determined that its convergence with
Rhat was ≤ 1.1 [15]. The settings of brm function in brms package were as follows:
Chains = 3, Iter = 30000 (100000 when random variables were included in the model),
Warmup = 15000 (50000 when random variables were included in the model), Thin = 2,
and Family = “normal.” When using the Shapiro-Wilk test on the BEPV, the null
hypothesis that followed the normal distribution was not rejected (P = 0.19). Thus, the
probability distribution for the response variable was a normal distribution.
Results
This study aimed to create a model (GLMM best model) that highly accurately
predicts the Css-trough of the initial dose plan for VCM using patient medical data
in the GLMM. Additionally, we assessed whether the VCM Css-trough values
(GLMMPV) calculated using the GLMM best model were closer to the BEPV than
the PMMPV. First, because we thought the medical data correlating to the differ-
ence (PMMPDQ) between BEPV and PMMPV would decrease the predictive error,
we extracted the medical data (fixed effect candidate 1) that was highly correlated
with the PMMPDQ. Next, to extract the medical data that could be applied to the
GLMM best model, we created a model (Eq. 4) including each the fixed effect can-
didate 1 item in the basic model (Eq. 3). Then, we selected the medical data (fixed
effect candidate 2) that made the WAIC of the model smaller (the smaller the
WAIC, the higher the predictive accuracy of the model and the smaller the
generalization error). Then, we created a model (Eq. 5) that included multiple fixed
effect candidate 2 items in the basic model and selected the model with the smal-
lest WAIC as the fixed effect model. We designated the medical data with the
largest PMMPDQ-related ICC as the random effect candidate items. We created
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multiple models that included the random effect candidate items in the fixed effect
model and selected the model with the smallest WAIC as the GLMM best model.
Finally, in to assess the GLMMPV accuracy, we investigated the simple linear
regression and R2 when the response variable was BEPV and the explanatory vari-
able was either the PMMPV or the GLMMPV. Details of the results are below.
GLMM best model construction
Extraction of medical data (fixed effect candidate 1) that correlated with the difference
(PMMPDQ) between BEPV and PMMPV (Fig. 3, procedure 2)
To increase the predictive accuracy of Css-trough when setting the VCM initial dose
plan, the difference between BEPV and PMMPV, which is the absolute value of the
PMMPDQ (Eq. 2), had to be reduced. Because the medical data items that correlated
highly with the PMMPDQ had a large effect on predictive accuracy, their inclusion in
the model would allow the predictive deviation to be reduced (that is, increase predict-
ive accuracy). First, we investigated the correlation between the PMMPDQ and all the
medical data items (continuous variables). The results indicated that 10 types of
medical data with absolute correlation coefficient values with the PMMPDQ of ≥ 0.2
(BUN/adjusted SCr, BUN, BUN/SCr, AST, Age, SCr, CLcr, SCr amount adjusted, single
dose, and daily dose, Table 2) were factors with a major effect on predictive accuracy.
To determine whether they could be used as fixed effect items in the model we created,
we conducted the following investigations on the 10 types of medical data as fixed
effect candidate 1 items.
Extracting medical data (fixed effect candidate 2) that was applicable as fixed effect (Fig. 3,
procedure 3)
To further extract the medical data that was applicable to the model from the
fixed effect candidate 1 items, we created a model (Eq. 4) that included each of
the fixed effect candidate 1 items in the basic model (Eq. 3) and calculated WAIC.
Declines in WAIC indicate a reduced prediction error. Of the models with the
fixed effect candidate 1, the one with a smaller WAIC than the basic model used
the following medical data: BUN/adjusted SCr, BUN, BUN/SCr, age, and SCr ad-
justed amount (Table 3). There is a high probability that these medical data items
Table 2 Correlation coefficient for fixed effect candidate 1 and PMMPDQ
Fixed effect candidate 1 (medical data) Correlation coefficient p-value







SCr adjusted amount -0.239 0.110
Single dose -0.263 0.078
Daily dose -0.279 0.060
Asterisks indicate p < 0.05
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can be used as an applicable fixed effect for the GLMM best model. Because the
BUN/adjusted SCr and BUN/SCr are similar parameters, we used only the BUN/
adjusted SCr with a low WAIC value. Therefore, we used the BUN/adjusted SCr,
BUN, age, and SCr adjusted amount as the fixed effect candidate 2 items in the
following investigation.
Fixed effect model determination (Fig. 3, procedure 4)
The GLMM model can use multiple fixed effect items. Therefore, we created a
model (Eq. 5) that included multiple fixed effect candidate 2 items in the basic
model (Eq. 3) and calculated the WAIC. The results indicate that the WAIC of the
model that simultaneously included BUN/adjusted SCr and SCr adjusted amount
was the lowest (253.45, Table 4). Based on this, we designated this model as the
fixed effect model.
Table 3 WAIC and the Coefficients of the variables when all fixed effect candidate 1 items are
included in basic model
Fixed effect candidate 1
(medical data)
Coefficient (l-95% CI, u-95% CI) WAIC
None (Basic model) - 258.42
BUN/adjusted SCr 0.1 (0.02, 0.17) 254.52a
BUN 0.09 (0.01, 0.17) 256.12a
BUN/SCr 0.08 (0.00, 0.16) 256.15a
AST 0.01 (-0.03, 0.05) 260.46
Age 0.04 (-0.01, 0.10) 257.51a
SCr 1.13 (-1.48, 3.78) 259.73
CLcr -0.01 (-0.07, 0.04) 260.6
SCr adjusted amount -16.09 (-32.54, 0.26) 256.18a
Single dose 0.00 (-0.01, 0.00) 260.6
Daily dose 0.00 (0.00, 0.00) 259.63
aWAIC of the model (Ep. 4) that included fixed effect candidate 1 item was smaller than the WAIC of the basic model (Ep. 3).
Smaller WAIC indicates decreased predictive error in the model
Table 4 WAIC when multiple fixed effect candidate 2 are included in the basic model
Fixed effect candidate 2 (medical data) WAIC
None (Basic model) 258.42
BUN/adjusted SCr and BUN 254.94
BUN/adjusted SCr and SCr adjusted amount 253.45a
BUN/adjusted SCr and Age 256.26
BUN and SCr adjusted amount 254.33
BUN and Age 256.05
SCr adjusted amount and Age 256.03
BUN/adjusted SCr and BUN and SCr adjusted amount 254.58
BUN/adjusted SCr and BUN and Age 256.83
BUN/adjusted SCr and SCr adjusted amount and Age 255.25
BUN and SCr adjusted amount and Age 256.14
BUN/adjusted SCr and BUN and SCr adjusted amount and Age 256.56
aLowest WAIC above. Lower WAIC indicates decreased predictive error in the model
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Extracting medical data (random effect) that was applicable as random effect (Fig. 3,
procedure 5)
Because medical data items (discrete variables) with a large PMMPDQ-related ICC
affect the predictive accuracy considerably, it is highly likely that they can be used as
applicable random effect items in the GLMM best model. Thus, we calculated the ICC
for all PMMPDQ-related medical data items (Table 5). The item with the largest
PMMPDQ-related ICC was sex (0.057) and, therefore, it was used as the random effect
candidate item in the following investigation.
GLMM best model determination (Fig. 3, procedure 6)
To determine the optimum predictive model (GLMM best model) that reduces
prediction error the most and includes fixed and random effects, we created mul-
tiple models that included sex (random effect) in the fixed effect model (the model
determined using Procedure 4 in Fig. 3) and calculated WAIC (Table 6). The
results indicated that the model including sex (random effect) in the PMMPV
(fixed effect) coefficient had the smallest WAIC (252.01). Therefore, we designated
this model as the GLMM best model.
Based on the above results, we determined the GLMM best model (Eq. 7)
would predict the Css-trough with high accuracy when establishing the VCM
initial dose plan.
Women
GLMMPV ¼ 0:977−0:081ð Þ  PMMPV þ 0:101  BUN=adjusted SCr − 12:899
 SCr adjusted amount
ð7AÞ
Men
GLMMPV ¼ 0:977þ 0:029ð Þ  PMMPV þ 0:101  BUN=adjusted SCr − 12:899
 SCr adjusted amount
ð7BÞ
The coefficients and their credible intervals (CIs) for all explanatory variables (fixed
and random effects) in the GLMM best model are shown in Table 7.
Table 5 ICC for medical data (discrete variables) related to PMMPDQ
Medical data (discrete variables) ICC l-95% CI u-95% CI
Sex 0.057 -0.032 0.991
Adjusted SCr 0.036 -0.041 0.989
Aged 75 or above 0.023 -0.039 0.987
No. of days from start of administration to blood test for
blood concentration trough
-0.043 -0.065 0.484
Age group (10-year intervals) -0.044 -0.117 0.392
Irregular interval administration -0.047 -0.047 -0.037
No. of doses -0.071 -0.140 0.358
Medical data (discrete variables) with a large ICC in relation to PMMPDQ have a high likelihood of being random effect
items suitable for use in the GLMM best model
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Assessing predictive accuracy of GLMM best model
First, we investigated the simple linear regression and R2 when the response variable
was BEPV, and the explanatory variable was either PMMPV or GLMMPV to assess the
BEPV-related accuracy of PMMPV and GLMMPV. The single linear regression slope
for PMMPV and GLMMPV was 0.902 and 1.060 respectively, and the intercept was
2.522 and -1.511 respectively. Furthermore, R2 was 0.513 and 0.623 respectively (Fig. 4).
These results indicate that GLMMPV was closer to BEPV than PMMPV. Therefore,
the GLMM best model may allow more accurate VCM Css-trough predictions.
Discussion
Figure 4b shows that the simple linear regression slope of BEPV and GLMMPV was
closer to 1 than that of BEPV and PMMPV was (Fig. 4a, GLMMPV, 1.060 and PMMPV,
0.902). Additionally, the simple linear regression intercept of BEPV and GLMMPV was
closer to 0 than that of the BEPV and PMMPV was (GLMMPV, -1.511 and PMMPV,
2.522). Additionally, because the R2 of BEPV and GLMMPV was higher than that of
BEPV and PMMPV (GLMMPV, 0.623 and PMMPV, 0.513), we were able to determine
that the GLMM best model created in this study predicted the VCM Css-trough with
better accuracy than the PMM did for the study subjects. Table 6 shows that the WAIC
of the GLMM best model (252.01) was smaller than that of the basic model (258.42,
equivalent to the model that predicted Css-trough from the PMM). This indicates that
generalization error is decreased in the GLMM best model. Therefore, we believe that
the GLMM best model can predict the VCM Css-trough of unknown patients with
greater accuracy than the PMM can.
Figure 4 shows that 4.35% (2/46) of patients had PMMPDQ of ≥10 μg/mL, but none
had GLMMPDQ of ≥10 μg/mL. Considering the effective blood concentration range of
the VCM Css-trough, a difference of ≥ 10 μg/mL in Css-trough predictions would raise
Table 6 WAIC when random effects are included in the fixed effect model
Fixed effect including random effect (Sex) WAIC
None (fixed effect model) 253.45
PMMPV 252.01a
BUN/adjusted SCr 252.29
SCr adjusted amount 252.34
PMMPV and BUN/adjusted SCr 253.65
PMMPV and SCr adjusted amount 253.39
BUN/adjusted SCr and SCr adjusted amount 252.69
PMMPV and BUN/adjusted SCr and SCr adjusted amount 253.11
aLowest WAIC above. Lower WAIC indicates decreased predictive error in the model
Table 7 All explanatory variables for the GLMM best model and their coefficient
Explanatory variables Coefficient l-95% CI u-95% CI
PMMPV (fixed effect) 0.977 0.314 1.960
BUN/adjusted SCr (fixed effect) 0.101 0.020 0.180
SCr adjusted amount (fixed effect) -12.899 -28.700 2.652
Sex: Female (random effect) -0.081 -1.201 0.592
Sex: Male (random effect) 0.029 -1.123 0.711
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concerns that the drug may be less effective and cause adverse effects. However, we
believe that the GLMM best model controls large prediction deviations like this.
Next, we investigated patients with major improvements in predictive accuracy
achieved by changing from the PMM to the GLMM best model in predicting VCM
Css-trough. Patient a shown in Fig. 4 had a PMMPDQ and GLMMPDQ of 7.90 and
0.64 μg/mL (the length of the dashed lines in Fig. 4a and b, respectively). Based on this,
the change from PMM to the GLMM best model allowed that predictive accuracy was
improved 7.26 μg/mL (7.90–0.64 μg/mL). Similarly, patients b and c showed a 3.53 and
3.23 μg/mL (4.80–1.27 and 6.00–2.77 μg/mL) improvement, respectively. The graph of
the changes in VCM blood concentration experienced by patient b (Fig. 5a) illustrates
that the PMMPV deviated greatly from the BEPV (the absolute PMMPDQ value was
large), which caused the blood concentration to fall outside the effective range.
However, since the GLMM best model predicted the Css-trough with high accuracy,
the GLMMPV was close to the BEPV (the absolute GLMMPDQ value was small) and
achieved the effective blood concentration range (Fig. 5b). Similarly, if the Css-trough
prediction accuracy can be increased and the achievement of an effective blood concen-
tration range can be accurately predicted when establishing the initial dose plan, then a
revised dose plan would be unnecessary. Furthermore, we found that the improvement
in the Css-trough prediction accuracy for the patients achieved using the GLMM best
model was related to high BUN/adjusted SCr values of these patients (patients a, b,
and c: 71.35, 34.52, and 32.17, respectively). It has been reported that when the BUN/
SCr is > 20, the estimation of renal function (CLcr) using the CG formula results in
overestimations [16]. Therefore, when establishing the initial dose plan using PMM for
patients a, b, and c, we assessed the CLcr at a higher than actual level, which led to
excessive VCM doses. We speculate that this further caused the deviation between the
A B
Fig. 4 Comparison of correlation of PMMPV with BEPV and GLMMPV with BEPV. Fig. 4a indicates correlation
of PMMPV and BEPV. Fig. 4b indicates correlation of GLMMPV and BEPV. Solid line is regression line with response
variable as BEPV and explanatory variable as either PMMPV or GLMMPV. If Css-trough can be accurately predicted
when establishing the initial dose plan, then all data plots will be located on the dotted line, and the solid and
dotted lines will be identical. The letters a, b, and c indicate patients who showed improved accuracy in their VCM
Css-trough predictions with the GLMM best model. The length of the dashed lines drawn vertically from a, b, and
c indicates (a) PMMPDQ (the difference between PMMPV and BEPV) and (b) GLMMPDQ (the difference between
GLMMPV and BEPV). The letters d, e, f, g and h indicate patients who showed the largest positive or negative
deviation in their predictions
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PMMPV and BEPV. However, when using the GLMM best model we included the
BUN/adjusted SCr (fixed effect), which corrected the overestimated renal function in
the CG formula and ultimately increased the VCM Css-trough prediction accuracy.
Nevertheless, there were also cases where the GLMM best model created in this
study did not improve the predictive accuracy of the Css-trough values. These patients
had large deviations (PMMPDQ) between PMMPV and BEPV, and the GLMM best
model did not improve the Css-trough prediction accuracy. For example, PMMPDQ
and GLMMPDQ of patient d showed large positive deviations (Fig. 4a and b, 11.2 and
9.4 μg/mL, respectively), and those of patient e also showed positive deviations (Fig. 4a
and b, 6.9 and 5.5 μg/mL, respectively). PMMPDQ and GLMMPDQ of patient f
showed negative deviations (Fig. 4a and b, -7.0 and -8.8 μg/mL, respectively). We
believe that these were likely attributable to the effect of changes in SCr after VCM
administration commenced. Our results showed that SCr of patient d was 0.60 mg/dL
before VCM administration, but rose to 0.85 mg/dL after VCM administration, and
SCr of patient e was risen from 1.05 mg/dL to 1.52 mg/dL. We considered that whose
renal functions were declined. Our results also showed that SCr of patient f was
1.20 mg/dL before VCM administration, but decreased to 0.82 mg/dL after VCM
administration, which we considered that whose renal function was improved. There-
fore, since the renal function of these patients changed after VCM administration
started (change in CLcr), the Css-trough prediction accuracy worsened, and the abso-
lute PMMPDQ and GLMMPDQ values increased. Furthermore, PMMPDQ and
GLMMPDQ of patient g showed large positive deviations (Fig. 4a and b, 8.8 and
6.4 μg/mL, respectively), and those of patient h also showed large positive deviations
(Fig. 4a and b, 10.3 and 8.5 μg/mL, respectively). We thought these were due mainly to
involvement of hypoalbuminemia. It has been reported that kidney function is overesti-
mated because of proximal tubule secretion of creatinine increases in patients with
hypoalbuminemia [17]. The serum albumin levels of patients g and h were 2.4 and
2.0 g/dL, respectively. We considered that overestimation of kidney function in patients
A B
Fig. 5 Blood concentration of VCM-time profiles in patient who was benefited more from GLMM best model than
from PMM. Patient b in Fig. 4 showed BEPV of 13.20 μg/mL, PMMPV of 8.40 μg/mL, and GLMMPV of 11.93 μg/mL.
a Patient’s PMMPV showed major differences with the BEPV, putting the level outside the effective
blood concentration range. Therefore, PMM led to major disadvantages in prediction. However, the GLMMPV
and BEPV in (b) were close and effective blood concentration range was reached, indicating the GLMM best
model was appropriate for making these predictions
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g and h led to excessive VCM doses, and rose Css-trough unexpectedly, resulting the
absolute PMMPDQ and GLMMPDQ values increased. To solve these problems, new
medical data must be extracted and included in the GLMM best model.
Conclusions
This study demonstrated that the GLMM best model we created for use with the
GLMM method in initial VCM dose planning allowed a more accurate Css-trough
prediction than PMM did. The GLMM best model increased the rate of achieving the
effective VCM blood concentration range. This may lead to reduce the revised dose
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